免疫介在性炎症疾患における ヤヌスキナーゼ阻害薬の相違
Rheumatology (Oxford) 2023;63(2):298–308 doi 10.1093/rheumatology/kead448
JAKis differ in structure, which affects their inhibitory concentration for different JAKs.
This review by Taylor, et al. compares the pharmacological profiles of JAKis, including abrocitinib, baricitinib, filgotinib, peficitinib, tofacitinib, and upadacitinib.